Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

Nature Medicine

Volumn 11, Issue 5, 2005, Pages 522-530

  Oliphant, Theodore ^a   Engle, Michael ^a   Nybakken, Grant E ^a   Doane, Chris ^a   Johnson, Syd ^b   Huang, Ling ^b   Gorlatov, Sergey ^b   Mehlhop, Erin ^a   Marri, Anantha ^a   Chung, Kyung Min ^a   Ebel, Gregory D ^c   Kramer, Laura D ^c   Fremont, Daved H ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Analytical Sciences   (United States)

^c WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E16; MONOCLONAL ANTIBODY E24; MONOCLONAL ANTIBODY E27; MONOCLONAL ANTIBODY E33; MONOCLONAL ANTIBODY E34; MONOCLONAL ANTIBODY E40; MONOCLONAL ANTIBODY E43; MONOCLONAL ANTIBODY E47; MONOCLONAL ANTIBODY E49; MONOCLONAL ANTIBODY E58; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; HUMAN; HUMAN CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA VIRUS INFECTION; SINGLE DRUG DOSE; VIRUS NEUTRALIZATION; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; CLONING, MOLECULAR; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MUTAGENESIS; NEUTRALIZATION TESTS; PLASMIDS; VIRAL ENVELOPE PROTEINS; WEST NILE FEVER; WEST NILE VIRUS; YEASTS;

ANIMALIA; FLAVIVIRUS; RNA VIRUSES; WEST NILE VIRUS;

EID: 21044448356     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1240     Document Type: Article

References (47)

1. Granwehr, B.P. et al. West Nile virus: where are we now? Lancet Infect. Dis. 4, 547-556 (2004).
2. Diamond, M.S., Shrestha, B., Mehlhop, E., Sitati, E. & Engle, M. Innate and adaptive immune responses determine protection against disseminated infection by West Nile Encephalitis virus. Viral Immunol. 16, 259-278 (2003).
3. Wang, T. & Fikrig, E. Immunity to West Nile virus. Curr. Opin. Immunol. 16, 519-523 (2004).
4. Ben-Nathan, D. et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating west nile virus infection in mice. J. Infect. Dis. 188, 5-12 (2003).
5. Engle, M. & Diamond, M.S. Antibody prophylaxis and therapy against West Nile Virus infection in wild type and immunodeficient mice. J. Virol. 77, 12941-12949 (2003).
6. Roehrig, J.T., Staudinger, L.A., Hunt, A.R., Mathews, J.H. & Blair, C.D. Antibody prophylaxis and therapy for flaviviral encephalitis infections. Ann. NY Acad. Sci. 951, 286-297 (2001).
7. Modis, Y., Ogata, S., Clements, D. & Harrison, S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA 100, 6986-6991 (2003).
8. Rey, F.A., Heinz, F.X., Mandl, C., Kunz, C. & Harrison, S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 Angstrom resolution. Nature 315, 291-298 (1995).
9. Rey, F.A. Dengue virus envelope glycoprotein structure: new insight into its interactions during viral entry. Proc. Natl. Acad. Sci. USA 100, 6899-6901 (2003).
10. Modis, Y., Ogata, S., Clements, D. & Harrison, S.C. Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319 (2004).
11. Zhang, W. et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol. 10, 907-912 (2003).
12. Mukhopadhyay, S., Kim, B.S., Chipman, P.R., Rossmann, M.G. & Kuhn, R.J. Structure of West Nile virus. Science 302, 248 (2003).
13. Bhardwaj, S., Holbrook, M., Shope, R.E., Barrett, A.D. & Watowich, S.J. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J. Virol. 75, 4002-4007 (2001).
14. Chu, J.J. et al. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J. Gen. Virol. 86, 405-412 (2005).
15. Beasley, D.W. & Barrett, A.D. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76, 13097-13100 (2002).
16. Volk, D.E. et al. Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J. Biol. Chem. 279, 38755-38761 (2004).
17. Beasley, D.W. & Aaskov, J.G. Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies. Virology 279, 447-458 (2001).
18. Crill, W.D. & Roehrig, J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75, 7769-7773 (2001).
19. Roehrig, J.T., Bolin, R.A. & Kelly, R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246, 317-328 (1998).
20. Cecilia, D. & Gould, E.A. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology 181, 70-77 (1991).
21. Wu, S.C., Lian, W.C., Hsu, L.C. & Liau, M.Y. Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. Virus Res. 51, 173-181 (1997).
22. Lin, B., Parrish, C.R., Murray, J.M. & Wright, P.J. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202, 885-890 (1994).
23. Diamond, M.S., Shrestha, B., Marri, A., Mahan, D. & Engle, M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77, 2578-2586 (2003).
24. Smithburn, K.C., Hughes, T.P., Burke, A.W. & Paul, J.H. A neurotropic virus isolated from the blood of a native of Uganda. Am. J. Trop. Med. Hyg. 20, 471-492 (1940).
25. Boder, E.T. & Wittrup, K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553-557 (1997).
26. LoBuglio, A.F. et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA 86, 4220-4224 (1989).
27. Meredith, R.F. et al. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. J. Nucl. Med. 32, 1162-1168 (1991).
28. Tao, M.H. & Morrison, S.L. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143, 2595-2601 (1989).
29. Shusta, E.V., Holler, P.D., Kieke, M.C., Kranz, D.M. & Wittrup, K.D. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat. Biotechnol. 18, 754-759 (2000).
30. Chambers, T.J., Halevy, M., Nestorowicz, A., Rice, C.M. & Lustig, S. West Nile virus envelope proteins: nucleotide sequence analysis of strains differing in mouse neuroinvasiveness. J. Gen. Virol. 79, 2375-2380 (1998).
31. Wu, K.P. et al. Structural basis of a Flavivirus recognized by its neutralizing antibody: Solution structure of the domain III of the Japanese Encephalitis virus envelope protein. J. Biol. Chem. 278, 46007-46013 (2003).
32. Kimura-Kuroda, J. & Yasui, K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 141, 3606-3610 (1988).
33. Virgin, H.W., Bassel-Duby, R., Fields, B.N. & Tyler, K.L. Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J. Virol. 62, 4594-4604 (1988).
34. Levine, B. et al. Antibody-mediated clearance of alphavirus infection from neurons. Science 254, 856-860 (1991).
35. Diamond, M. et al. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J. Virol. 74, 4957-4966 (2000).
36. Ebel, G.D., Carricaburu, J., Young, D., Bernard, K.A. & Kramer, L.D. Genetic and phenotypic variation of West Nile virus in New York, 2002-2003. Am. J. Trop. Med. Hyg. 71, 493-500 (2004).
37. Karabatsos, N. International Catalogue of Arboviruses Including Certain Other Viruses of Vertebrates 3rd edn (American Society of Tropical Medicine and Hygiene, San Antonio, 1985).
38. Delenda, C., Staropoli, I., Frenkiel, M.P., Cabanie, L. & Deubel, V. Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. J. Gen. Virol. 75, 1569-1578 (1994).
39. Lanciotti, R.S. et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286, 2333-2337 (1999).
40. Harlow, E. & Lane, D. Antibodies: A Laboratory Manual, p. 714 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1988).
41. Boder, E.T. & Wittrup, K.D. Optimal screening of surface-displayed polypeptide libraries. Biotechnol. Prog. 14, 55-62 (1998).
42. Kabat, E.A., Wu, T.T., Perry, H., Gottesman, K. & Foeller, C. Sequences of Proteins of Immunological Interest. p. 3242 (US National Institutes of Health, Bethesda, Maryland, 1991).
43. Matsuda, F. et al. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J. Exp. Med. 188, 2151-2162 (1998).
44. Ravetch, J.V., Siebenlist, U., Korsmeyer, S., Waldmann, T. & Leder, P. Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. Cell 27, 583-591 (1981).
45. Klobeck, H.G., Meindl, A., Combriato, G., Solomon, A. & Zachau, H.G. Human immunoglobulin kappa light chain genes of subgroups II and III. Nucleic Acids Res. 13, 6499-6513 (1985).
46. Klobeck, H.G. et al. Subgroup IV of human immunoglobulin K light chains is encoded by a single germline gene. Nucleic Acids Res. 13, 6515-6529 (1985).
47. Hieter, P.A., Maizel, J.V., Jr. & Leder, P. Evolution of human immunoglobulin kappa J region genes. J. Biol. Chem. 257, 1516-1522 (1982).